Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29594166 | 1.00 | ALDH1A1 (0.56) | ALDH1A1TDP1SMN1; SMN2MAPK1LMNA | |
| SCHEMBL399453 | 0.86 | TDP1 (0.69) | ALDH1A1TDP1SMN1; SMN2MAPK1LMNA | |
| SCHEMBL29593678 | 0.86 | TDP1 (0.69) | ALDH1A1TDP1SMN1; SMN2MAPK1LMNA | |
| SCHEMBL13176003 | 0.86 | SMN1; SMN2 (0.50) | ALDH1A1TDP1SMN1; SMN2LMNAHTT | |
| SCHEMBL5177671 | 0.86 | ALDH1A1 (0.48) | ALDH1A1TDP1SMN1; SMN2LMNAHTT | |
| Hydrochloric Acid SCHEMBL10875998 | 0.85 | TDP1 (0.68) | ALDH1A1TDP1SMN1; SMN2MAPK1LMNA | |
| SCHEMBL9594291 | 0.85 | TDP1 (0.55) | ALDH1A1TDP1SMN1; SMN2HTTHDAC1 | |
| SCHEMBL8751487 | 0.84 | SMN1; SMN2 (0.54) | ALDH1A1TDP1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30492996 | 0.84 | SMN1; SMN2 (0.68) | ALDH1A1SMN1; SMN2MAPK1LMNAALOX15 | |
| SCHEMBL1851780 | 0.84 | SMN1; SMN2 (0.68) | ALDH1A1SMN1; SMN2MAPK1LMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | claimed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | claimed |
| CN-114394974-A | Polysubstituted triaryl macrocyclic compounds and uses thereof | 中国药科大学 | 2022-04-26 | — | — | CN | disclosed |
| US-9616064-B2 | Rho kinase inhibitors and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-8901315-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140073799-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-13 | — | — | US | disclosed |
| CN-103492389-A | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors | ORIGENIS GMBH | 2014-01-01 | — | — | CN | disclosed |
| EP-1775298-B1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO CO LTD (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| EP-0317859-A2 | Azo dyes containing polyethylenimine | BASF Aktiengesellschaft (DE) | 1989-05-31 | — | — | EP | disclosed |
| EP-0087706-B1 | CATIONIC HYDRAZONE DYES, THEIR MANUFACTURE AND THEIR USE | BAYER AG (DE) | 1986-07-30 | — | — | EP | disclosed |
| US-4496719-A | 3H-Indol-2-yl cationic hydrazone dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1985-01-29 | — | — | US | disclosed |
| EP-0087706-A2 | Cationic hydrazone dyes, their manufacture and their use | BAYER AG (DE) | 1983-09-07 | — | — | EP | disclosed |
| EP-0014318-B1 | REACTIVE DYESTUFFS, THEIR PREPARATION AND THEIR USE FOR DYEING MATERIALS CONTAINING HYDROXYL OR AMIDE GROUPS | BAYER AG (DE) | 1983-02-23 | — | — | EP | disclosed |
| US-4286962-A | Phthalocyanine reactive dyestuffs, their preparation and their use for dyeing materials containing hydroxyl groups or amide groups | BAYER AKTIENGESELLSCHAFT (DE) | 1981-09-01 | — | — | US | disclosed |
| US-4267107-A | WATER SOLUBLE PHTHALOCYANINE DYES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-12 | — | — | US | disclosed |
| EP-0014318-A1 | Reactive dyestuffs, their preparation and their use for dyeing materials containing hydroxyl or amide groups | BAYER AG (DE) | 1980-08-20 | — | — | EP | disclosed |
| US-4062838-A | LACQUERS, PRINTING INKS, YELLOW TO ORANGE | CIBA-GEIGY CORPORATION (US) | 1977-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073799-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | PDE7A, PDE7B, PDE3B | ALDH1A1 2864/4885TDP1 811/4885SMN1; SMN2 4191/4885 |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | ROCK1, ROCK2, RHOA | ALDH1A1 3573/4885TDP1 630/4885SMN1; SMN2 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.